Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834984 · ClinicalTrials.gov registry record · NA
Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women
A NA study of Gastrointestinal Disease Symptoms, sponsored by Colorado State University.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06834984: Recruiting NA study of Gastrointestinal Disease Symptoms, sponsored by Colorado State University.
NCT06834984 is a NA study of Gastrointestinal Disease Symptoms that is actively recruiting participants, run by Colorado State University. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06834984, a NA study of Gastrointestinal Disease Symptoms, is actively recruiting participants, sponsored by Colorado State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebiotics, probiotics, and postbiotics, impacts functional gastrointestinal health, markers of intestinal inflammation and immune health, and influences mood and behavior. The primary outcome will be to assess gastrointestinal health using bowel movement tracking, self-report and objective assessments of gastrointestinal symptom severity, stool levels of short chain fatty acids, changes in the gut microbiota, including recovery of LGG and BB-12, and functional measures of the microbiome. Secondary outcomes will include stool and blood markers of gut barrier function and intestinal inflammation, immune health, and self-assessments of stress, anxiety, sleep, and quality of life.
Primary Outcome
Gas chromatography will be used to measure changes in SCFA production in stool.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Prebiotic, probiotic, postbiotic combination
Study Locations (1)
Colorado
- Colorado State University Food and Nutrition Clinical Research Laboratory - Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT06834984 shows while recruiting
NCT06834984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Gastrointestinal Disease Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06834984 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06834984 about?
NCT06834984 is a clinical study titled "Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women". The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebiotics, probiotics, and postbiotics, impacts functional gastrointestinal health, markers of intestinal inflammation and immune health, and influences mood and behavior. The primary out...
What is the current status of trial NCT06834984?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-05-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06834984 study?
This clinical trial studies the following conditions: Gastrointestinal Disease Symptoms.
What interventions are being tested in trial NCT06834984?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Prebiotic, probiotic, postbiotic combination (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06834984?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06834984 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06834984's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI